[Comment] Adjuvant therapy in colon cancer: less is more

The results of the SCOT trial reported by Timothy Iveson and colleagues1 in The Lancet Oncology establish a new standard of care in the adjuvant treatment of stage III colon cancer. The investigators showed the non-inferiority of treatment with 3 months of adjuvant chemotherapy versus 6 months of the same treatment in terms of 3 year disease-free survival. These results endorse the adoption of a shorter duration of adjuvant chemotherapy. Patients treated with the shorter duration of therapy had significant reductions in adverse events, including a more than halving in the number of grade 2 or worse sensory neuropathy events.
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Tags: Comment Source Type: research